NO20052646D0 - Method of treating cognitive decline due to sleep deprivation and stress - Google Patents
Method of treating cognitive decline due to sleep deprivation and stressInfo
- Publication number
- NO20052646D0 NO20052646D0 NO20052646A NO20052646A NO20052646D0 NO 20052646 D0 NO20052646 D0 NO 20052646D0 NO 20052646 A NO20052646 A NO 20052646A NO 20052646 A NO20052646 A NO 20052646A NO 20052646 D0 NO20052646 D0 NO 20052646D0
- Authority
- NO
- Norway
- Prior art keywords
- stress
- cognitive decline
- sleep deprivation
- treating cognitive
- decline due
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/18—Sulfonamides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/536—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with carbocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/549—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame having two or more nitrogen atoms in the same ring, e.g. hydrochlorothiazide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Hospice & Palliative Care (AREA)
- Anesthesiology (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyrrole Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Heterocyclic Compounds Containing Sulfur Atoms (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US43973503P | 2003-01-13 | 2003-01-13 | |
| PCT/US2004/000706 WO2004062616A2 (en) | 2003-01-13 | 2004-01-13 | Method of treating cognitive decline due to sleep deprivation and stress |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| NO20052646D0 true NO20052646D0 (no) | 2005-06-02 |
| NO20052646L NO20052646L (no) | 2005-08-11 |
Family
ID=32713510
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20052646A NO20052646L (no) | 2003-01-13 | 2005-06-02 | Method of treating cognitive decline due to sleep deprivation and stress |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US20060276462A1 (no) |
| EP (1) | EP1592464A4 (no) |
| JP (1) | JP2006516283A (no) |
| KR (1) | KR20050094840A (no) |
| CN (1) | CN1764460A (no) |
| AU (1) | AU2004204814B2 (no) |
| BR (1) | BRPI0406736A (no) |
| CA (1) | CA2509251A1 (no) |
| EA (1) | EA200501117A1 (no) |
| MX (1) | MXPA05007389A (no) |
| NO (1) | NO20052646L (no) |
| NZ (1) | NZ540468A (no) |
| PL (1) | PL378366A1 (no) |
| UA (1) | UA80317C2 (no) |
| WO (1) | WO2004062616A2 (no) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20050215889A1 (en) * | 2004-03-29 | 2005-09-29 | The Board of Supervisory of Louisiana State University | Methods for using pet measured metabolism to determine cognitive impairment |
| EP1960373A2 (en) * | 2005-11-22 | 2008-08-27 | NeuroSearch A/S | Novel quinoxaline derivatives and their medical use |
| AU2007291848B2 (en) * | 2006-08-31 | 2012-01-12 | The Governors Of The University Of Alberta | Method of inhibition of respiratory depression using positive allosteric AMPA receptor modulators |
| SI2144506T1 (sl) * | 2007-01-03 | 2012-01-31 | Servier Lab | 3-substituirana-(1,2,3)-benzotriazinon spojine za povečanje glutamatnih sinaptičnih odgovorov |
| AU2008360162A1 (en) * | 2008-07-28 | 2010-02-04 | Nihon Medi-Physics Co., Ltd. | Technique for Detecting Neurodegenerative Disorders |
| CA2774715C (en) | 2009-07-27 | 2018-04-03 | Gilead Sciences, Inc. | Fused heterocyclic compounds as ion channel modulators |
| US20110257186A1 (en) * | 2010-04-15 | 2011-10-20 | Staubli Ursula V | Compositions and methods for treating visual disorders |
| NZ604478A (en) | 2010-07-02 | 2014-12-24 | Gilead Sciences Inc | Fused heterocyclic compounds as ion channel modulators |
| EA028156B9 (ru) | 2011-05-10 | 2018-01-31 | Джилид Сайэнс, Инк. | Конденсированные гетероциклические соединения в качестве модуляторов ионных каналов |
| TWI478908B (zh) | 2011-07-01 | 2015-04-01 | Gilead Sciences Inc | 作為離子通道調節劑之稠合雜環化合物 |
| NO3175985T3 (no) | 2011-07-01 | 2018-04-28 | ||
| US10555916B2 (en) | 2013-01-25 | 2020-02-11 | Case Western Reserve University | NMDAR antagonist for the treatment of pervasive development disorders |
| US9857971B2 (en) * | 2013-12-02 | 2018-01-02 | Industrial Technology Research Institute | System and method for receiving user input and program storage medium thereof |
| JP7444727B2 (ja) | 2020-08-05 | 2024-03-06 | 株式会社 資生堂 | 感触評価方法および感触評価装置 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1156043B1 (en) | 1992-07-24 | 2003-11-12 | The Regents Of The University Of California | Drugs that enhance synaptic responses mediated by ampa receptors |
| US5852008A (en) | 1995-01-24 | 1998-12-22 | The Regents Of The University Of California | Heteroatom substituted benzoyl derivatives that enhance synaptic response mediated by receptors |
| US5650409A (en) | 1995-06-02 | 1997-07-22 | Cortex Pharmaceuticals, Inc. | Benzoyl piperidines/pyrrolidines for enhancing synaptic response |
| US5891871A (en) | 1996-03-21 | 1999-04-06 | Cocensys, Inc. | Substituted 2,3-benzodiazepin-4-ones and the use thereof |
| US5736543A (en) | 1996-04-03 | 1998-04-07 | The Regents Of The University Of California | Benzoxazines for enhancing synaptic response |
| US6110935A (en) * | 1997-02-13 | 2000-08-29 | The Regents Of The University Of California | Benzofurazan compounds for enhancing glutamatergic synaptic responses |
| AU745641B2 (en) * | 1997-10-27 | 2002-03-28 | Cortex Pharmaceuticals, Inc. | Treatment of schizophrenia with ampakines and neuroleptics |
| US5985871A (en) | 1997-12-24 | 1999-11-16 | Cortex Pharmaceuticals, Inc. | Benzoxazine compounds for enhancing synaptic response |
| ATE556710T1 (de) * | 2004-01-26 | 2012-05-15 | Cortex Pharma Inc | Verbesserung der durch ampakine induzierten erleichterung von synaptischen reaktionen durch cholinesterase-inhibitoren |
-
2004
- 2004-01-13 US US10/541,687 patent/US20060276462A1/en not_active Abandoned
- 2004-01-13 BR BR0406736-3A patent/BRPI0406736A/pt not_active IP Right Cessation
- 2004-01-13 EP EP04701787A patent/EP1592464A4/en not_active Withdrawn
- 2004-01-13 UA UAA200508006A patent/UA80317C2/uk unknown
- 2004-01-13 CN CNA2004800021731A patent/CN1764460A/zh active Pending
- 2004-01-13 MX MXPA05007389A patent/MXPA05007389A/es active IP Right Grant
- 2004-01-13 AU AU2004204814A patent/AU2004204814B2/en not_active Ceased
- 2004-01-13 PL PL378366A patent/PL378366A1/pl not_active Application Discontinuation
- 2004-01-13 WO PCT/US2004/000706 patent/WO2004062616A2/en active Application Filing
- 2004-01-13 EA EA200501117A patent/EA200501117A1/ru unknown
- 2004-01-13 KR KR1020057012912A patent/KR20050094840A/ko not_active Application Discontinuation
- 2004-01-13 JP JP2006500909A patent/JP2006516283A/ja active Pending
- 2004-01-13 CA CA002509251A patent/CA2509251A1/en not_active Abandoned
- 2004-01-13 NZ NZ540468A patent/NZ540468A/en unknown
-
2005
- 2005-06-02 NO NO20052646A patent/NO20052646L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| WO2004062616A3 (en) | 2005-12-15 |
| NO20052646L (no) | 2005-08-11 |
| EP1592464A4 (en) | 2011-03-09 |
| US20060276462A1 (en) | 2006-12-07 |
| NZ540468A (en) | 2008-03-28 |
| AU2004204814A1 (en) | 2004-07-29 |
| PL378366A1 (pl) | 2006-04-03 |
| WO2004062616A2 (en) | 2004-07-29 |
| UA80317C2 (en) | 2007-09-10 |
| AU2004204814B2 (en) | 2009-10-08 |
| KR20050094840A (ko) | 2005-09-28 |
| EA200501117A1 (ru) | 2006-02-24 |
| BRPI0406736A (pt) | 2005-12-20 |
| JP2006516283A (ja) | 2006-06-29 |
| CA2509251A1 (en) | 2004-07-29 |
| MXPA05007389A (es) | 2006-02-10 |
| CN1764460A (zh) | 2006-04-26 |
| EP1592464A2 (en) | 2005-11-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO20052646D0 (no) | Method of treating cognitive decline due to sleep deprivation and stress | |
| DE602004016970D1 (de) | P38 inhibitor und anwendungsverfahren dafür | |
| ATE389618T1 (de) | Anschwemmfiltermedien und herstellungs- und verwendungsverfahren | |
| GB2419931B (en) | Silent chain and method of producing same | |
| ATE414556T1 (de) | Verwendung von il-18-inhibitoren zur behandlung und/oder prävention von peripheren gefässkrankheiten | |
| ATE389649T1 (de) | Substituierte amin-derivate und deren verwendung zur behandlung von angionese-bedingten erkrankungen | |
| ITMI20050262A1 (it) | Sostanze composizioni e metodi di trattamento dell'alopecia | |
| DE60238742D1 (de) | Gate-Struktur und Verfahren zur Herstellung | |
| DE60116066D1 (de) | Titanium mit verminderter anfälligkeit für verfärbung in der atmosphäre und herstellungsverfahren dafür | |
| IS2654B (is) | Essítalópram hýdróbrómíð og aðferð til framleiðslu þess | |
| DK1890570T3 (da) | Tandbørstehoved og fremgangsmåde til fremstilling deraf | |
| ATE395075T1 (de) | Verwendung von il-18 inhibitoren zur behandlung und/oder prävention von atherosklerose | |
| DE60317693D1 (de) | Methode und verwendung von thermostabilen rna-ligasen | |
| DE60322898D1 (de) | Verwendung von isoflavonen zur förderung des schlankheitseffekts | |
| ATE380558T1 (de) | Verwendung von il-18 hemmern zur behandlung und/oder prävention von herzkrankheiten | |
| DE60317431D1 (de) | Flachkabelbaum und Herstellungsverfahren desselben | |
| DE60238174D1 (de) | Fluoropolymere und Herstellungs- und Verwendungsverfahren | |
| ATE418337T1 (de) | Verwendung von dihydroimidazolonen zur behandlung von epilepsie bei hunden | |
| FI20031448A (fi) | Tarralaminaatti ja menetelmä tarralaminaatin valmistamiseksi | |
| FI20031678A0 (fi) | Näytteen käsittelymenetelmä ja järjestely siihen | |
| ATE376416T1 (de) | Verwendung von ambroxol zur behandlung von chronischen schmerzen | |
| FI20041464A (fi) | Salpaelektroidi sekä kiinnitysmenetelmä ja menetelmän käyttäminen | |
| SE0400709D0 (sv) | Composition and method of treatment | |
| SE0400614D0 (sv) | Composition and method of treatment | |
| DE60304471D1 (de) | Eine elektrochemisch reagierende zusammensetzung und herstellungsverfahren dafür |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC2A | Withdrawal, rejection or dismissal of laid open patent application |